Ongoing Developments in Biologic Therapy




Registration benefits include:
Access to CME/CE programs and certification
Free subscription to Biologic Bulletin newsletter
Reminders of new CME/CE activities
REGISTER NOW

Library : Biblography
Biblography
Our searchable, sortable bibliography is the most comprehensive listing of articles, posters, abstracts, and CME programs on biologic therapy in psoriasis available on the Web. Links to these documents are provided where possible.

Author:
Publication:
Primary Keyword:
Secondary Keyword:
Sort By:
  

1026 Total Entries Printer-friendly version Jump to page

A Ammoury, F El Sayed, R Dhaybi, et al. Palmoplantar pustulosis should not be considered as a variant of psoriasis J Eur Acad Dermatol Venereol. 2007
Date Published: July 2007
Keywords:
View Abstract  

Abramovits W. Raptiva (efalizumab). SKINmed. 2004;3:37-38.
Date Published: January 2004
Keywords: antigens, CD11a, efalizumab, monoclonal antibodies, psoriasis
View Abstract  

Abramovits W, Gupta AK. New therapy update: Enbrel (etanercept). SKINmed. 2004;3:333-335.
Date Published: November 2004
Keywords: administration, adverse effects, biological response modifiers, dose-response, etanercept, immunoglobulin G, psoriasis, psoriatic arthritis, receptors, T cells, tumor necrosis factor (TNF)
View Abstract  

Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis. Pharmacoeconomics. 2008;26:121-9
Date Published: January 2008
Keywords:
View Abstract  

Adisen E, Karaca F, Gürer MA. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents. Clin Exp Dermatol. 2008;33:164-6
Date Published: March 2008
Keywords:
View Abstract  

Aggarwal BB, Natarajan K. Tumor necrosis factors: developments during last decade [review]. Eur Cytokine Netw. 1996;7:93-124
Date Published: April 1996
Keywords: lymphotoxin, receptors, tumor necrosis factor (TNF)
View Abstract  

Ahmad K, Rogers S. Two years of experience with etanercept in recalcitrant psoriasis. Br J Dermatol.
Date Published: April 2007
Keywords:
View Abstract  

Ahmad K, Roger S. Development of Crohn disease in a patient on etanercept for psoriasis. Br J Dermatol. 2007
Date Published: June 2007
Keywords:
View Abstract  

Ahmadi A, Barikbin B, Naseri M, et al. The effect of HESA-A on psoriasis vulgaris. J Drugs Dermatol. 2008;7:559-61
Date Published: June 2008
Keywords:
View Abstract  

Akhyani M, Ehsani AH, Robati RM, et al. The lipid profile in psoriasis: a controlled study J Eur Acad Dermatol Venereol. 2007
Date Published: June 2007
Keywords:
View Abstract  

Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: a systematic review J Rheumatol. 2008;35:1354-8
Date Published: July 2008
Keywords:
View Abstract  

Al-Awadhi A, Dale P, McKendry RJ. Pancytopenia associated with low dose methotrexate therapy: a regional survey. J Rheumatol. 1993;20:1121-1125
Date Published: July 1993
Keywords: adverse effects, dose-response, methotrexate, pancytopenia, psoriasis, psoriatic arthritis, rheumatoid arthritis
View Abstract  

Alcaide AJ, Barrera MV, Habicheyn S, et al. Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection. J Eur Acad Dermatol Venereol. 2008:[Epub ahead of print]
Date Published: March 2008
Keywords:
View Abstract  

Dehnavi R, de Roos A, Rabelink TJ, et al. Elevated CRP levels are associated with increased carotid atherosclerosis independent of visceral obesity. Atherosclerosis. 2008 Feb 18. [Epub ahead of print]
Date Published: February 2008
Keywords:
View Abstract  

Allanore Y, Kahan A, Sellam J, et al. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta. 2005;[Epub ahead of print].
Date Published: September 2005
Keywords: arthritis, atherogenic index, cholesterol, C-reactive protein, cytokines, inflammation, infliximab, metabolism, refractory, rheumatoid arthritis, serum, TNF-alfa, tumor necrosis factor (TNF)
View Abstract  

Al-Salem IH. Striking and rapid improvement of plaque psoriasis with infliximab: a report of two cases. Dermatology. 2003;207:54-56.
Date Published: January 2003
Keywords: administration, dermatologic agents, dosage, dose-response, follow-up studies, infliximab, intravenous, methotrexate, monoclonal antibodies, psoriasis, psoriatic arthritis, tumor necrosis factor (TNF)


Alstergren P, Larsson PT, Kopp S. Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis. Scand J Rheumatol. 2008;37:155-7
Date Published: March 2008
Keywords:
View Abstract  

Altobelli E, Petrocelli R, Marziliano C, et al. Family history of psoriasis and age at disease onset in Italian patients with psoriasis. Br J Dermatol. 2007;156:1400-1
Date Published: June 2007
Keywords:
View Abstract  

Al-Za'abi AM, Ghazarian D, Greenberg GR, et al. Eruptive tufted angiomas in a patient with Crohn's disease. J Clin Pathol. 2005;58:214-216.
Date Published: February 2005
Keywords: angioblastoma, Crohn's disease, gastrointestinal agents, hemangioma, immunosuppression, infliximab, intravenous, lesions, monoclonal antibodies, neoplasms, skin, skin neoplasms, tufted angioma
View Abstract  

Amevive. Amevive® (alefacept) package insert. Cambridge, Mass: Biogen Inc; 2004.
Date Published: March 2004
Keywords: administration, adverse effects, alefacept, Amevive, dosage, efficacy, hypersensitivity, immunogenicity, immunosuppression, infections, injection-site reactions, liver, lymphocytes, lymphopenia, malignancy, pharmacodynamics, pharmacokinetics, prescribing information, safety
View Article  Download PDF  

Amital H, Ingber A, Rubinow A. Infliximab-induced remission of extensive plaque psoriasis. Isr Med Assoc J. 2003;5:827-828.
Date Published: November 2003
Keywords: administration, combination therapy, dermatologic agents, dosage, infliximab, intravenous, methotrexate, monoclonal antibodies, oral, psoriasis, remission
View Abstract  

Ammoury A, El Sayed F, Dhaybi R, et al. Palmoplantar pustulosis should not be considered as a variant of psoriasis. J Eur Acad Dermatol Venereol. 2008;22:392-3
Date Published: March 2008
Keywords:
View Abstract  

Anandacoomarasamy A, Kannangara S, Barnsley L. Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis. Intern Med J. 2005;35:638-640.
Date Published: October 2005
Keywords: arthritis, infliximab, rheumatoid arthritis, vasculitis
View Abstract  

Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227-1236
Date Published: April 2005
Keywords: ACR, antirheumatic agents, dactylitis, dermatologic agents, efficacy, enthesitis, infliximab, intravenous, monoclonal antibodies, PASI, psoriasis, psoriatic arthritis
View Abstract  

Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol. 2008;35:869-76
Date Published: May 2008
Keywords:
View Abstract